FRANKLIN, Mass., Oct. 9, 2019 /PRNewswire/ -- A new study
published in the Journal of Shoulder and Elbow Surgery
reports that the OVO® with Inlay Glenoid Shoulder Arthroplasty
System demonstrates excellent clinical benefits, including pain
relief and increased range of motion in patients with glenohumeral
(GH) arthritis. The OVO® with Inlay Glenoid Shoulder
Arthroplasty System is made by Arthrosurface®, Inc., a global
leader in joint preservation technology.
"Our initial results show that nonspherical HH [humeral head]
resurfacing, combined with inlay glenoid replacement, is a viable
outpatient technique for GH arthritis across patients with
concentric and eccentric glenoid morphology," the study states.
"Results showed no significant differences in patient-reported
outcomes including pain relief, function and satisfaction,
comparing preoperative concentric with nonconcentric glenoid
morphology. We found a significant improvement in range of motion
that was consistent across glenoid stages."
The study, conducted by the Department of Orthopedic Surgery at
The Cleveland Clinic Foundation, involved a retrospective case
series including 31 shoulders in 29 patients, with an average age
of 58.5 years old. Osteoarthritis (OA) of the GH joint can be a
disabling condition resulting in pain and loss of function.
According to the Arthritis Foundation, it is estimated that nearly
1 in 3 people over the age of 60 have shoulder OA to some
degree. Positive outcomes of the study included significant
improvement in Penn Shoulder Score, improved range of motion when
compared to traditional stemmed total shoulder arthroplasty (TSA)
in conventional and reverse configurations, patient pain relief and
functional results for both eccentric and concentric glenoids.
"This truly is a revolutionary stemless total shoulder, which
combines the concept of anatomic restoration with an aspherical
head design that more closely replicates the normal patient
anatomy," said Dr. Anthony Miniaci,
MD of the Cleveland Clinic. "This combination of an aspherical head
and inlay glenoid has shown to be effective in not only active and
younger patients but in those with glenohumeral arthritis, even in
the face of posterior subluxation and bone erosion."
The study, "Total shoulder arthroplasty with nonspherical
humeral head and inlay glenoid replacement: clinical results
comparing concentric and nonconcentric glenoid stages in primary
shoulder arthritis," can be viewed here.
About Arthrosurface®, Inc.
Arthrosurface®, Inc. is a
global leader in joint preservation technology, manufacturing less
invasive joint replacements that are clinically proven to help
patients stay active by increasing range of motion and reducing
pain. The company's product portfolio features more than 150
different surface implant curvatures for the knee, shoulder, hip,
ankle, wrist and toe that are designed to treat upper and lower
extremity orthopedic conditions caused by trauma, injury and
arthritic disease. More than 100,000 patients have been treated
with Arthrosurface implants since the company was founded in 2002.
Arthrosurface markets and distributes its products in the United States and around the world, with
more than 5,000 surgeons currently using Arthrosurface products in
more than 25 countries. For more information, please visit our
website at www.arthrosurface.com.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/clinical-study-demonstrates-equally-impressive-outcomes-for-any-condition-of-glenoid-using-the-arthrosurface-ovo-with-inlay-glenoid-total-shoulder-300934703.html
SOURCE Arthrosurface, Inc.